Egyesült Államok - angol - NLM (National Library of Medicine)

sanofi pasteur inc. - neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen (unii: re9a0h8oab) (neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen - unii:re9a0h8oab), neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (unii: 2j57k2523t) (neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen - unii:2j57k2523t), neisseria meningitidis group y capsular polysaccharide diphtheria - neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen 4 ug in 0.5 ml - menactra® , meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, y and w-135. menactra is approved for use in individuals 9 months through 55 years of age. menactra does not prevent n meningitidis serogroup b disease. severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or crm197 -containing vaccine, or to any component of menactra [see description (11) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to menactra during pregnancy. to enroll in or obtain information about the registry, call sanofi pasteur at 1-800-822-2463. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects an

Izrael - angol - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 10a; pneumococcal polysaccharide serotype 11a; pneumococcal polysaccharide serotype 12f; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 15b; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 22f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 33f; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 8; pneumococcal polysaccharide serotype 9v - suspension for injection - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 33f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 22f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 15b 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 12f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 11a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 10a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 8 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - prevenar 20 is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older.

Egyesült Államok - angol - NLM (National Library of Medicine)

merck sharp & dohme llc - streptococcus pneumoniae type 1 capsular polysaccharide antigen (unii: h9noi61uh1) (streptococcus pneumoniae type 1 capsular polysaccharide antigen - unii:h9noi61uh1), streptococcus pneumoniae type 2 capsular polysaccharide antigen (unii: e11p4f3x4s) (streptococcus pneumoniae type 2 capsular polysaccharide antigen - unii:e11p4f3x4s), streptococcus pneumoniae type 3 capsular polysaccharide antigen (unii: 4fvb62aff1) (streptococcus pneumoniae type 3 capsular polysaccharide antigen - unii:4fvb62aff1), strep - streptococcus pneumoniae type 1 capsular polysaccharide antigen 25 ug in 0.5 ml - pneumovax® 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, and 33f). pneumovax 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. do not administer pneumovax 23 to individuals with a history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine. [see description (11).] risk summary all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. available human data from clinical trials of

Izrael - angol - Ministry of Health

glaxo smith kline (israel) ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - suspension for injection - pneumococcal polysaccharide serotype 23f 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 3 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 1 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 3 mcg / 0.5 ml - pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated - active immunisation against invasive disease, pneumonia and acute otitis media caused by strepococcus pneumoniae serotypes 1, 4,5,6b,7f,9v,14,18c ,19f and 23f in infants and children from 6 weeks up to 5 years of age

Izrael - angol - Ministry of Health

pfizer pharmaceuticals israel ltd - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w - 135 polysaccharide; neisseria meningitidis group y polysaccharide - powder and solvent for solution for injection - neisseria meningitidis group y polysaccharide 5 mcg; neisseria meningitidis group w - 135 polysaccharide 5 mcg; neisseria meningitidis group c polysaccharide 5 mcg; neisseria meningitidis group a polysaccharide 5 mcg - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135 and y.

Írország - angol - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - haemophilus influenzae type b polysaccharide; conjugate of haemophilus influenzae type b capsular polysaccharide (prp) and tetanus toxoid - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with toxoids

Írország - angol - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - conjugate of haemophilus influenzae type b capsular polysaccharide (polyribosylribitol phosphate) and tetanus; conjugate of neisseria meningitides c capsular polysaccharide and tetanus toxoid (mean tt/ps ratio :1) - powder and solvent for solution for injection - 0.5 millilitre(s) - hemophilus influenzae b, combinations with meningococcus c, conjugated

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - meningococcal polysaccharide group a,meningococcal polysaccharide group c,meningococcal polysaccharide group w135,meningococcal polysaccharide group y,tetanus toxoid -

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Jordánia - angol - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع خوري - khoury drug store - pnuemococcal polysaccharide serotypes serotype 6b= 4.4 mcg, pneumococcal polysaccharide serotypes 1, 3,4,5,6a,7f,9v,14,18c,19a,19f &23f= 2.2 mcg - serotype 6b= 4.4 mcg, 1, 3,4,5,6a,7f,9v,14,18c,19a,19f &23f= 2.2 mcg